Stage II in the development of Eph/ephrin based tumor targeting reagents: Optimisation of drug efficacy and delivery

基于 Eph/ephrin 的肿瘤靶向试剂开发的第二阶段：药物功效和递送的优化

• 批准号: nhmrc : 284418
• 负责人: A/Pr Martin Lackmann
• 金额: $ 13.61万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/stage-ii-development-efficacy-delivery/77687
• 关键词: Stage; II; development; Eph; ephrin

In the final stage of cancer, including melanoma, tumor cells gain the ability to spread, a process called metastasis. Altered communication between cancer and normal cells is one of the causes of this invasive characteristic. We have started the development of novel agents that target and modulate proteins on the cell surface that control these properties and are found in metastatic tumors. We propose to refine the targeting and killing properties of these agents for early clinical testing.

在癌症的最后阶段，包括黑色素瘤，肿瘤细胞获得了扩散的能力，这个过程被称为转移。癌细胞和正常细胞之间通讯的改变是这种侵袭性特征的原因之一。我们已经开始了针对和调节细胞表面蛋白质的新型药物的开发，这些蛋白质控制着这些特性，并在转移性肿瘤中发现。我们建议完善这些药物的靶向和杀伤特性，以便进行早期临床试验。